A multicenter analysis of patients with invasive lobular carcinoma—the second most common histological subtype of invasive breast cancer in the U.S.—showed that, despite its prevalence, ILC is detected later and has worse outcomes than the predominant subtype of invasive breast cancer, known as invasive ductal carcinoma, or no special type.
“Patients are counting on us, and this remains the best time to be involved in cancer research,” W. Kimryn Rathmell said to The Cancer Letter.
